Their results are published in the May issue of the Journal of Lipid Research. This scientific breakthrough may help prevent diabetes by targeting treatments to higher-risk individuals.
Dr. Faraj’s research aims at exploring new mechanisms that could favour the development of type 2 diabetes and various dietary interventions that may help prevent diabetes within the Canadian population. For this project, her team studied the function of the adipose tissue (or body fat), which is specialized in storing excess energy from the diet as fat. In humans, adipose tissue is primarily located beneath skin, but can also be found around internal organs.
“Following a meal, dietary fat is transported to different locations in the body, including adipose tissue,” says Dr. Faraj. “However, if the adipose tissue is not functioning properly, fat accumulates instead in non-adipose tissue such as the liver, muscle and pancreas, which decreases the body’s ability to utilize dietary sugar. Many people have a common misconception that it is better to block adipose tissue function to reduce obesity but, in fact, poorly-functional adipose tissue can increase the risk for type 2 diabetes and other cardiovascular diseases.”
The accumulation of fat in the liver increases the production of low-density lipoprotein (LDL), the particles commonly referred to as “bad cholesterol.” While the human body needs a normal level of LDL to ensure cell growth and repair, high levels can cause a build-up of plaque in the artery walls. This subsequently leads to narrowing of the arteries and increased risk of heart attack and stroke. A high number of LDL particles is also an established risk factor for cardiovascular disease.
“We examined the relationship between the number of LDL particles and adipose tissue function in postmenopausal overweight and obese women,” explain Simon Bissonnette and Huda Salem, graduate students on Dr. Faraj’s team and first authors of the study. “These women were all considered healthy because they were non-smokers, did not take any medication and did not have any chronic diseases like diabetes or cardiovascular disease. We discovered that a high number of LDL particles is not only a consequence of dysfunctional adipose tissue, but that it also plays an active role in causing adipose tissue to become less functional.”
“Our study’s results suggest that reducing the number of LDL particles can improve adipose tissue function and, in turn, reduce the risk of developing both type 2 diabetes and cardiovascular disease in obese individuals,” adds Dr. Faraj. “This discovery may help us identify people with a higher risk of developing such cardiometabolic diseases and target them with pharmaceutical or dietary interventions to prevent the onset of disease.”
“The Canadian Institutes of Health Research is proud to support Dr. May Faraj in leading her team to make these discoveries that will positively impact the health of Canadians,” says Dr. Phil Sherman, Scientific Director at CIHR’s Institute of Nutrition, Metabolism and Diabetes. “Arming Canadians with information about whether they are at risk for type 2 diabetes and how they can avoid it is key to lowering the rate of this preventable condition.” /2
About the research project
Several IRCM researchers collaborated in this study, including Robert Dufour (Director of the Nutrition, Metabolism and Atherosclerosis clinic), Alexis Baass (medical consultant), Hanny Wassef, Nathalie St-Pierre, and Annie Tardif, as well as members of the research platform on obesity, metabolism and diabetes (PROMD). The research project was funded by the Canadian Institutes of Health Research (CIHR) and the Canada Foundation for Innovation (CFI).
For more information, please refer to the article summary published online by the Journal of Lipid Research: http://www.jlr.org/content/54/5/1466.
About May Faraj
May Faraj obtained a PhD in Experimental Medicine from McGill University. She is an associate research professor in the Department of Nutrition at the Université de Montréal, and an invited scientist in the Metabolic Diseases research unit at the IRCM. Dr. Faraj is also a Principal Investigator at the Montreal Diabetes Research Center and a member of the Ordre professionnel des diététistes du Québec. She holds a New Investigator Award from CIHR and is a Junior 2 Research Scholar from the Fonds de recherche du Québec – Santé. For more information, visit www.ircm.qc.ca/faraj.
About the IRCM
Founded in 1967, the Institut de recherches cliniques de Montréal (www.ircm.qc.ca) is currently comprised of 36 research units in various fields, namely immunity and viral infections, cardiovascular and metabolic diseases, cancer, neurobiology and development, systems biology and medicinal chemistry. It also houses three specialized research clinics, eight core facilities and three research platforms with state-of-the-art equipment. The IRCM employs 425 people and is an independent institution affiliated with the Université de Montréal. The IRCM Clinic is associated to the Centre hospitalier de l’Université de Montréal (CHUM). The IRCM also maintains a long-standing association with McGill University. The IRCM is funded, in part, by the Quebec ministry of Higher Education, Research, Science and Technology.
About the Canadian Institutes of Health Research (CIHR) The Canadian Institutes of Health Research (CIHR) (www.cihr-irsc.gc.ca) is the Government of Canada’s health research investment agency. CIHR’s mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened health care system for Canadians. Composed of 13 Institutes, CIHR provides leadership and support to more than 14,100 health researchers and trainees across Canada.
For more information and to schedule an interview with Dr. Faraj, please contact
- Julie Langelier
Communications Officer (IRCM)
- Lucette Thériault
Communications Director (IRCM)